Molnupiravir—A novel oral anti-SARS-CoV-2 agent

研究成果: Article同行評審

19 引文 斯高帕斯(Scopus)


Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral antiviral agents are urgently needed to treat coronavirus disease-2019 (COVID-19), block SARS-CoV-2 trans-mission, and prevent progression to severe illness. Molnupiravir (formerly EIDD-2801), a prodrug of beta-D-N4-hydroxycytidine (EIDD-1931) and an inhibitor of RNA-dependent RNA polymerase, possesses significant activity against SARS-CoV-2. Its prophylactic efficacy has been evidenced in a ferret model. Two phase-I trials (NCT04392219 and NCT04746183) have demonstrated that oral mol-nupiravir is safe and well-tolerated at therapeutic doses. After five-days of oral molnupiravir therapy, satisfactory efficacies, assessed by eliminating nasopharyngeal virus in patients with early and mild COVID-19, were disclosed in two phase-II trials (NCT04405739 and NCT 04405570). Two phase-II/III trials, NCT04575597 and NCT04575584, with estimated enrollments of 1850 and 304 cases, respec-tively, are ongoing. The NCT04575597 recently released that molnupiravir significantly reduced the risk of hospitalization or death in adults experiencing mild or moderate COVID-19. To benefit individual and public health, clinical applications of molnupiravir to promptly treat COVID-19 patients and prevent SARS-CoV-2 transmission may be expected.

出版狀態Published - 2021 11月

All Science Journal Classification (ASJC) codes

  • 微生物學
  • 生物化學
  • 藥理學、毒理學和藥劑學 (全部)
  • 微生物學(醫學)
  • 傳染性疾病
  • 藥學(醫學)


深入研究「Molnupiravir—A novel oral anti-SARS-CoV-2 agent」主題。共同形成了獨特的指紋。